Rather than a fixed conversion factor, we have developed a method that uses a sliding scale factor to estimate VLDL-C with high precision from triglycerides and non-HDL cholesterol levels. This method to estimate LDL-C was derived and validated in 1,350,908 human samples.
Specific advantages include:
• LDL-C estimates by this novel method are more concordant with those by directly measured LDLC
• Highly accurate classification of LDL-C concentrations lower than 100 mg/dL, especially in patients with elevated triglyceride concentrations.
• Using an adjustable factor for estimation of VLDL-C provides the most accurate quantification of LDL-C from patient to patient.
• Provides substantially higher-fidelity estimates than the Friedewald equation or any other existing estimation method using data from the standard lipid panel.
• Can be easily implemented in most laboratory reporting systems at virtually no cost.
• Unlike the Friedewald method, this novel method of LDL-C estimation was derived and validated from a very large clinical population dataset shown to be representative of the general population with distribution of major serum lipids nearly identical to the NHANES 2007-2008 survey.
Looking for Partners:
To commercialize the technology as an accurate method for LDL-C estimation from the standard lipid profile.
Stage of Development:
Pre-clinical
Data Availability:
Technology derived and validated in 1,350,908 human samples.
Publications/Associated Cases:
JAMA. 2013 Nov 20;310(19):2043-4.
J Am Coll Cardiol. 2013 Aug 20;62(8):732-9
